Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 7/20 | 1.00 |
| ▸ | TUBB | P07437 | 7/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 7/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 7/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 7/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 7/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 7/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.57 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063036 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4967209 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30466670 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29815038 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1764918 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7499124 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7496691 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23671618 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23671617 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29815036 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405843-B1 | METHOD FOR PRODUCING AMINOSTILBENE DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-20 | — | — | EP | claimed |
| US-6930205-B2 | Process for preparing aminostilbene derivatives | AJINOMOTO CO., INC. (JP) | 2005-08-16 | — | — | US | claimed |
| US-20040176642-A1 | Process for preparing aminostilbene derivatives | AJINOMOTO CO. INC (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1405843-A1 | METHOD FOR PRODUCING AMINOSTILBENE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-04-07 | — | — | EP | claimed |
| CN-116332802-B | Tubulin and NRP1 double-target compound and preparation method and application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116332802-A | Tubulin and NRP1 double-target compound and preparation method and application thereof | 中国药科大学 | 2023-06-27 | — | — | CN | disclosed |
| US-11279678-B2 | 5-fluorouracil derivatives, preparation methods and uses thereof | SHANGHAI ECUST BIOMEDICINE CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20210230122-A1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION METHODS AND USES THEREOF | SHANGHAI ECUST BIOMEDICINE CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-10952975-B2 | Compositions and methods for treatment of cancer | TERMAN DAVID S (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200297658-A1 | Compositions and Methods for Treatment of Cancer | TERMAN DAVID S (US) | 2020-09-24 | — | — | US | disclosed |
| US-RE45907-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-RE45720-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | MATEON THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035008-A2 | FUNCTIONALIZED STILBENE DERIVATIVES AS IMPROVED VASCULAR TARGETING AGENTS | OXIGENE, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003000645-A1 | METHOD FOR PRODUCING AMINOSTILBENE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2003-01-03 | — | — | WO | disclosed |
| EP-0641767-B1 | Cytotoxic stilbene derivatives and pharmaceutical composition containing them | AJINOMOTO KK (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5731353-A | ANTICARCINOGENIC AGENTS | AJINOMOTO CO., INC. (JP) | 1998-03-24 | — | — | US | disclosed |
| US-5525632-A | ANTICARCINOGENIC AGENTS | AJINOMOTO CO., LTD. (JP) | 1996-06-11 | — | — | US | disclosed |
| EP-0641767-A1 | Cytotoxic stilbene derivatives and pharmaceutical composition containing them | Ajinomoto Co., Inc. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176642-A1 | Process for preparing aminostilbene derivatives | DHPS, AASDHPPT, NPEPPS | TUBB1 697/4885TUBB4A 1312/4885TUBB 945/4885 |
| US-20200297658-A1 | Compositions and Methods for Treatment of Cancer | CD47, VEGFA, VHL | TUBB1 633/4885TUBB4A 804/4885TUBB 475/4885 |
| US-20030149003-A1 | Functionalized stilbene derivatives as improved vascular targeting agents | FLT1, FLT4, KDR | TUBB1 9/4885TUBB4A 6/4885TUBB 17/4885 |
| US-10952975-B2 | Compositions and methods for treatment of cancer | CD47, VEGFA, VHL | TUBB1 633/4885TUBB4A 804/4885TUBB 475/4885 |
| US-20030220404-A1 | Process for the preparation of combretastatins | TGFB2, HMGCR, TGFB1 | TUBB1 577/4885TUBB4A 1286/4885TUBB 709/4885 |
| US-11279678-B2 | 5-fluorouracil derivatives, preparation methods and uses thereof | VEGFA, FLT4, FAU | TUBB1 310/4885TUBB4A 208/4885TUBB 242/4885 |
| US-20210230122-A1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION METHODS AND USES THEREOF | VEGFA, FLT4, FAU | TUBB1 310/4885TUBB4A 208/4885TUBB 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.